Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088329872> ?p ?o ?g. }
- W3088329872 endingPage "S812" @default.
- W3088329872 startingPage "S812" @default.
- W3088329872 abstract "The phase 1 trial of sotorasib, a KRASG12C inhibitor, demonstrated a favorable safety profile and preliminary antitumor activity in pts with advanced solid tumors harboring KRAS p.G12C. Here, we present durability of clinical benefit and biomarker data in pts with NSCLC. Key eligibility criteria include KRAS p.G12C mutation and prior systemic anticancer treatment (tx). Primary endpoint is safety; key secondary endpoints include objective response rate (ORR), disease control rate (DCR), duration of response (DOR), and progression-free survival (PFS). KRAS p.G12C mutant allele frequency (MAF) and PD-L1 level were examined. As of July 17, 2019, 40 pts with NSCLC (22 female [55.0%], median age: 68.0 years [range: 49-77]) were enrolled. Data cutoff date was March 25, 2020. 31 (77.5%) and 19 pts (47.5%) received ≥ 2 and 3 prior lines of therapy, respectively. Median follow-up was 10.2 (range: 8.3–19.0) months (mos). 3 pts (7.5%) had adverse events leading to discontinuation. There were no dose-limiting toxicities or fatal tx-related adverse events. Median PFS for all pts was 6.9 (range: 1.2–13.9) mos. ORR was 30% (95% Cl, 16.56–46.53). DOR ranged from 1.6 (+) to 12.7 mos, with 7 of 12 responders still in response at data cutoff. DCR was 92.5% (95% Cl, 79.61–98.43). 18 pts (45.0%) had progressive disease. At data cutoff, 10 pts (25.0%) were on study without disease progression, and 9 pts (22.5%) died. 18 pts (45.0%) (5 partial response (PR), 12 stable disease (SD), 1 progressive disease (PD)) had KRAS p.G12C MAF data available. There was no significant association between KRAS p.G12C MAF and response (Wilcoxon P = 0.80 for PR vs SD). 11 pts (27.5%) had PD-L1 data available. The median PD-L1 tumor proportion score [TPS] was 3% (range: 1–5) in 2 pts with PR, 0% (range: 0–0) in 8 pts with SD, and 75% (range: 75–75) in the pt with PD (Wilcoxon P = 0.044 for PR vs. SD). In pts with heavily pretreated NSCLC, durable responses to sotorasib were seen, with the majority of pts achieving disease control leading to a median PFS of 6.9 months. The current limited dataset suggests that neither KRAS p.G12C MAF nor PD-L1 expression level predicts response to sotorasib." @default.
- W3088329872 created "2020-10-01" @default.
- W3088329872 creator A5000063580 @default.
- W3088329872 creator A5005968330 @default.
- W3088329872 creator A5009829154 @default.
- W3088329872 creator A5010370929 @default.
- W3088329872 creator A5025646273 @default.
- W3088329872 creator A5026095888 @default.
- W3088329872 creator A5038343178 @default.
- W3088329872 creator A5039660281 @default.
- W3088329872 creator A5043862738 @default.
- W3088329872 creator A5063149530 @default.
- W3088329872 creator A5066558658 @default.
- W3088329872 creator A5068824818 @default.
- W3088329872 creator A5069777765 @default.
- W3088329872 creator A5072339418 @default.
- W3088329872 creator A5073605756 @default.
- W3088329872 creator A5087836238 @default.
- W3088329872 date "2020-09-01" @default.
- W3088329872 modified "2023-09-30" @default.
- W3088329872 title "1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)" @default.
- W3088329872 doi "https://doi.org/10.1016/j.annonc.2020.08.1571" @default.
- W3088329872 hasPublicationYear "2020" @default.
- W3088329872 type Work @default.
- W3088329872 sameAs 3088329872 @default.
- W3088329872 citedByCount "6" @default.
- W3088329872 countsByYear W30883298722021 @default.
- W3088329872 countsByYear W30883298722022 @default.
- W3088329872 countsByYear W30883298722023 @default.
- W3088329872 crossrefType "journal-article" @default.
- W3088329872 hasAuthorship W3088329872A5000063580 @default.
- W3088329872 hasAuthorship W3088329872A5005968330 @default.
- W3088329872 hasAuthorship W3088329872A5009829154 @default.
- W3088329872 hasAuthorship W3088329872A5010370929 @default.
- W3088329872 hasAuthorship W3088329872A5025646273 @default.
- W3088329872 hasAuthorship W3088329872A5026095888 @default.
- W3088329872 hasAuthorship W3088329872A5038343178 @default.
- W3088329872 hasAuthorship W3088329872A5039660281 @default.
- W3088329872 hasAuthorship W3088329872A5043862738 @default.
- W3088329872 hasAuthorship W3088329872A5063149530 @default.
- W3088329872 hasAuthorship W3088329872A5066558658 @default.
- W3088329872 hasAuthorship W3088329872A5068824818 @default.
- W3088329872 hasAuthorship W3088329872A5069777765 @default.
- W3088329872 hasAuthorship W3088329872A5072339418 @default.
- W3088329872 hasAuthorship W3088329872A5073605756 @default.
- W3088329872 hasAuthorship W3088329872A5087836238 @default.
- W3088329872 hasBestOaLocation W30883298721 @default.
- W3088329872 hasConcept C121608353 @default.
- W3088329872 hasConcept C126322002 @default.
- W3088329872 hasConcept C141071460 @default.
- W3088329872 hasConcept C143998085 @default.
- W3088329872 hasConcept C197934379 @default.
- W3088329872 hasConcept C203092338 @default.
- W3088329872 hasConcept C2776256026 @default.
- W3088329872 hasConcept C2778715236 @default.
- W3088329872 hasConcept C2778822529 @default.
- W3088329872 hasConcept C2779134260 @default.
- W3088329872 hasConcept C2779177807 @default.
- W3088329872 hasConcept C2781187634 @default.
- W3088329872 hasConcept C31760486 @default.
- W3088329872 hasConcept C526805850 @default.
- W3088329872 hasConcept C535046627 @default.
- W3088329872 hasConcept C71924100 @default.
- W3088329872 hasConcept C81729549 @default.
- W3088329872 hasConcept C90924648 @default.
- W3088329872 hasConceptScore W3088329872C121608353 @default.
- W3088329872 hasConceptScore W3088329872C126322002 @default.
- W3088329872 hasConceptScore W3088329872C141071460 @default.
- W3088329872 hasConceptScore W3088329872C143998085 @default.
- W3088329872 hasConceptScore W3088329872C197934379 @default.
- W3088329872 hasConceptScore W3088329872C203092338 @default.
- W3088329872 hasConceptScore W3088329872C2776256026 @default.
- W3088329872 hasConceptScore W3088329872C2778715236 @default.
- W3088329872 hasConceptScore W3088329872C2778822529 @default.
- W3088329872 hasConceptScore W3088329872C2779134260 @default.
- W3088329872 hasConceptScore W3088329872C2779177807 @default.
- W3088329872 hasConceptScore W3088329872C2781187634 @default.
- W3088329872 hasConceptScore W3088329872C31760486 @default.
- W3088329872 hasConceptScore W3088329872C526805850 @default.
- W3088329872 hasConceptScore W3088329872C535046627 @default.
- W3088329872 hasConceptScore W3088329872C71924100 @default.
- W3088329872 hasConceptScore W3088329872C81729549 @default.
- W3088329872 hasConceptScore W3088329872C90924648 @default.
- W3088329872 hasLocation W30883298721 @default.
- W3088329872 hasOpenAccess W3088329872 @default.
- W3088329872 hasPrimaryLocation W30883298721 @default.
- W3088329872 hasRelatedWork W2148536479 @default.
- W3088329872 hasRelatedWork W2301234320 @default.
- W3088329872 hasRelatedWork W2587903744 @default.
- W3088329872 hasRelatedWork W2590242426 @default.
- W3088329872 hasRelatedWork W2729289325 @default.
- W3088329872 hasRelatedWork W2886193299 @default.
- W3088329872 hasRelatedWork W3088329872 @default.
- W3088329872 hasRelatedWork W3137379589 @default.
- W3088329872 hasRelatedWork W4254376100 @default.
- W3088329872 hasRelatedWork W4318904193 @default.
- W3088329872 hasVolume "31" @default.
- W3088329872 isParatext "false" @default.